NCT01323634 - Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

519

Participants

Timeline

Start Date

March 18, 2011

Primary Completion Date

December 14, 2011

Study Completion Date

December 14, 2011

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg

inhalation powder

DRUG

Fluticasone Propionate 250mcg/ salmeterol 50mcg

inhalation powder

Trial Locations (50)

10717

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

14057

GSK Investigational Site, Berlin

19055

GSK Investigational Site, Schwerin

27607

GSK Investigational Site, Raleigh

28207

GSK Investigational Site, Charlotte

29379

GSK Investigational Site, Union

29615

GSK Investigational Site, Greenville

29640

GSK Investigational Site, Easley

30342

GSK Investigational Site, Atlanta

32822

GSK Investigational Site, Orlando

42431

GSK Investigational Site, Madisonville

43215

GSK Investigational Site, Columbus

60596

GSK Investigational Site, Frankfurt am Main

63141

GSK Investigational Site, St Louis

65183

GSK Investigational Site, Wiesbaden

70000

GSK Investigational Site, Bucharest

76712

GSK Investigational Site, Waco

90048

GSK Investigational Site, Los Angeles

125367

GSK Investigational Site, Moscow

194291

GSK Investigational Site, Saint Petersburg

248007

GSK Investigational Site, Kaluga

300310

GSK Investigational Site, Timișoara

305035

GSK Investigational Site, Kursk

400371

GSK Investigational Site, Cluj-Napoca

500112

GSK Investigational Site, Brasov

500283

GSK Investigational Site, Brasov

650002

GSK Investigational Site, Kemerovo

656024

GSK Investigational Site, Barnaul

656038

GSK Investigational Site, Barnaul

700115

GSK Investigational Site, Iași

720284

GSK Investigational Site, Suceava

256 30

GSK Investigational Site, Benešov

678 31

GSK Investigational Site, Blansko

767 55

GSK Investigational Site, Kroměříž

697 33

GSK Investigational Site, Kyjov

276 01

GSK Investigational Site, Mělník

741 01

GSK Investigational Site, Nový Jičín

337 01

GSK Investigational Site, Rokycany

674 01

GSK Investigational Site, Třebíč

13-200

GSK Investigational Site, Działdowo

82-300

GSK Investigational Site, Elblag

88-100

GSK Investigational Site, Inowrocław

40-018

GSK Investigational Site, Katowice

31-159

GSK Investigational Site, Krakow

60-214

GSK Investigational Site, Poznan

54-239

GSK Investigational Site, Wroclaw

011794

GSK Investigational Site, Bucharest

030317

GSK Investigational Site, Bucharest

050159

GSK Investigational Site, Bucharest